What Causes Protein Misfolding and Its Role in Disease

Protein misfolding happens when a protein fails to reach or maintain its correct three-dimensional shape, and the causes range from inherited genetic mutations to everyday cellular wear and tear. Every protein your body makes starts as a chain of amino acids that must fold into a precise structure to do its job, and anything that disrupts that process can set the stage for disease. The consequences extend far beyond a single broken molecule: misfolded proteins can clump together, overwhelm the cell’s repair systems, and even corrupt neighboring proteins. The result is a strikingly wide spectrum of illnesses, from Alzheimer’s and Parkinson’s disease to cystic fibrosis and certain heart conditions.

How Mutations Knock Proteins Out of Shape

The most straightforward cause of misfolding is a change in the gene that encodes the protein. A single amino acid swap can weaken the internal contacts that hold a protein’s structure together, making it thermodynamically unstable. Research on the dystrophin protein illustrates this clearly. In muscular dystrophy, specific missense mutations in dystrophin’s actin-binding domain reduce its helical content and eliminate the cooperative melting behavior seen in the normal protein. Some mutants exist in a loosely structured “molten globule” state, while others retain a near-normal fold but melt at lower temperatures. All four studied mutants undergo severe misfolding and aggregation, forming cross-beta structures similar to those found in amyloid diseases. The net effect is a drop in functional dystrophin concentration, which directly contributes to muscle degeneration.¹

Mutations do not all break proteins the same way. Work on the enzyme methylmalonyl-CoA mutase, which is defective in a metabolic disorder called methylmalonic acidemia, has sorted missense mutations into distinct categories of biochemical damage: some reduce overall protein levels because the protein misfolds and gets destroyed before it can function, some make the protein heat-sensitive so it falls apart at normal body temperature, some impair enzymatic activity directly, and some interfere with the protein’s ability to use its cofactor.² This kind of stratification matters because different types of misfolding damage call for different therapeutic strategies.

Environmental Stressors That Push Proteins Out of Shape

Even a protein with a perfectly normal gene sequence can misfold if the cell’s environment becomes hostile. Oxidative stress is a major culprit. When reactive molecules accumulate inside cells, they can oxidize the sulfur-containing amino acids in proteins, creating abnormal chemical bridges called non-native disulfide bonds. Experiments using the oxidative agent menadione have shown that this kind of chemical damage destabilizes proteins in a dose-dependent fashion, causing them to unfold, expose normally hidden greasy surfaces, and clump into detergent-insoluble aggregates. The damaged proteins also trigger the cell’s heat-shock response, ramping up production of protective chaperone molecules.³

Oxidative stress is not the only environmental threat. High temperatures denature proteins by adding thermal energy that overwhelms the weak interactions holding the fold together. Extreme pH changes can protonate or deprotonate charged amino acids, disrupting salt bridges. Heavy metals can bind where they should not, distorting the structure. And certain toxins or drugs can interfere with the cellular machinery proteins depend on for folding assistance. In each case, the core problem is the same: something tilts the balance away from the native fold and toward a disordered or aggregation-prone state.

Translation Speed and Cotranslational Folding

A less obvious but increasingly appreciated cause of misfolding involves the speed at which a protein is manufactured. As a ribosome reads the messenger RNA and strings amino acids together, the growing chain begins to fold before it is even finished. The pace of this process is not uniform. The ribosome pauses at certain points, and these pauses appear to be tightly coordinated with the folding of individual protein domains.⁴ Rare codons are overrepresented at domain boundaries across all branches of life, and synonymous codon changes that speed up or slow down translation at the wrong points can alter the protein’s final shape, its solubility, and its resistance to degradation.

This “translational rhythm” is conserved among messenger RNAs that encode proteins with related folds. When researchers have disrupted this rhythm through synonymous codon substitutions, the resulting proteins sometimes adopt misfolded conformations that persist even after they leave the ribosome.⁵ Patches of charged amino acids in the growing chain can also slow or stall translation, affecting how the emerging protein navigates its folding landscape. The implication is striking: two proteins with identical amino acid sequences can end up with different structures simply because the codons used to encode them alter the timing of synthesis.⁶

The Cell’s Built-In Defense Systems

Cells are not defenseless against misfolded proteins. They have evolved overlapping quality-control systems that detect, refold, or destroy aberrant molecules. The first line of defense is molecular chaperones, particularly the HSP70 family. These proteins bind to exposed hydrophobic surfaces on misfolded proteins, shielding them from the surrounding water and giving them another chance to fold correctly. In work on TDP-43 fragments linked to neurodegenerative disease, overexpression of HSP70 significantly reduced the formation of protein clumps called inclusion bodies, though it could not fully dissolve aggregates that had already formed.⁷

Chaperones often work in teams. The co-chaperone DNAJB6 cooperates with HSP70 to suppress aggregation of alpha-synuclein, the protein implicated in Parkinson’s disease. A mutant form of DNAJB6 unable to hand off misfolded substrates to HSP70 lost this protective effect entirely, demonstrating that the two chaperones function synergistically rather than independently.⁸

When a protein cannot be refolded, the cell tags it for destruction. The ubiquitin-proteasome system attaches small ubiquitin molecules to misfolded proteins, marking them for breakdown by the proteasome. Eukaryotic cells have specialized enzymes that distinguish misfolded proteins from correctly folded ones, ensuring that functional molecules are left alone.⁹ This system is essential for preventing the toxic buildup of damaged proteins.¹⁰

Some aggregates grow too large or too stable for the proteasome to handle. In that case, a process called aggrephagy steps in: the cell wraps clumps of misfolded protein in a double membrane and delivers them to lysosomes for digestion. Individual misfolded proteins can be sent to the proteasome or handed off via chaperone-mediated autophagy, but true aggregates generally require this bulk degradation route.¹¹ Researchers have also identified a receptor called CCT2 that can direct solid protein aggregates to autophagy independently of ubiquitin tagging, adding yet another layer to the cell’s clearance toolkit.¹²

The Unfolded Protein Response

When misfolded proteins pile up in the endoplasmic reticulum, a specialized alarm system called the unfolded protein response kicks in. It operates through three signaling branches. One branch slows down the production of new proteins, giving the cell breathing room so fewer molecules require folding at once. A second branch activates a gene-expression program that ramps up chaperone production and other repair factors. A third triggers splicing of specific messenger RNAs to boost the cell’s folding capacity further.¹³ Together, these branches aim to restore the balance between folding demand and folding capacity. If the stress is too severe or lasts too long, though, the same pathways can switch from protective to destructive, ultimately triggering programmed cell death.

Neurodegenerative Diseases and Toxic Aggregates

The diseases most visibly linked to protein misfolding are the neurodegenerative conditions: Alzheimer’s, Parkinson’s, Huntington’s, and amyotrophic lateral sclerosis (ALS). In each case, specific proteins misfold and accumulate in or around nerve cells, eventually killing them. The toxic species are not always the large fibrillar deposits visible under a microscope. Growing evidence points to smaller, soluble clusters called oligomers as the most harmful forms. Oligomers damage cells through several routes: they can punch holes in cell membranes, interfere with normal signaling molecules, and form pore-like channels that disrupt the cell’s ionic balance.¹⁴

One of the most unsettling features of these diseases is that misfolded proteins can spread. In a process with clear parallels to prion diseases, misfolded protein seeds can structurally corrupt normal copies of the same protein, recruiting them into growing aggregates. These seeds propagate from cell to cell, which helps explain the characteristic pattern of progressive brain degeneration seen in Alzheimer’s and Parkinson’s disease.¹⁵ The concept of a purely proteinaceous infectious agent was first proposed decades ago and eventually crystallized in Stanley Prusiner’s coining of the term “prion,” a concept that challenged the central dogma that all pathogens must carry nucleic acid to replicate.¹⁶

Misfolding Diseases Beyond the Brain

Protein misfolding is not strictly a neurological problem. Amyloidosis is a group of disorders in which misfolded proteins deposit as insoluble fibrils in organs throughout the body, causing progressive damage.¹⁷ In light-chain amyloidosis, a small clone of immune cells produces abnormal antibody fragments that misfold, aggregate, and deposit in the heart, kidneys, liver, and nerves. Without effective treatment, the organ damage is irreversible and eventually fatal.¹⁸

Cystic fibrosis offers a different angle on the problem. Here, the issue is not toxic aggregation but loss of function. The most common mutation in cystic fibrosis produces a chloride channel protein (CFTR) that misfolds and gets flagged for destruction before it ever reaches the cell surface. The cell’s quality-control machinery, which is supposed to protect against misfolded proteins, ends up working against the patient by eliminating a protein that, if given the chance, could still partially function. The result is reduced chloride conductance in the lungs and other organs, leading to thick mucus buildup and chronic infections.¹⁹

Aging and the Collapse of Protein Maintenance

Age is the single largest risk factor for most protein misfolding diseases, and the reason ties directly to the cell’s declining ability to maintain its proteins. As cells age, their chaperone networks become less efficient, their proteasomes slow down, and cumulative oxidative damage produces a growing burden of structurally compromised proteins.²⁰

Modeling of this process suggests a vicious cycle: as irreparably damaged proteins accumulate, they increasingly monopolize the available chaperones, pulling them away from the newly made proteins that need folding assistance. Eventually a tipping point is reached where the production of functional proteins can no longer keep pace with the loss from misfolding, aggregation, and damage. That tipping point correlates with cell death.²¹ This framework explains why Alzheimer’s, Parkinson’s, and systemic amyloidosis overwhelmingly strike later in life: the aggregation-prone proteins may be present for decades, but the cell’s capacity to manage them erodes with time.

Liquid Droplets as a Gateway to Aggregation

A newer piece of the puzzle involves a phenomenon called liquid-liquid phase separation. Cells naturally concentrate certain proteins into dense, droplet-like compartments that lack a surrounding membrane. These compartments are useful: they organize biochemical reactions, regulate gene expression, and speed up signaling. But many of the proteins implicated in neurodegenerative diseases, including those linked to ALS and frontotemporal dementia, are especially prone to phase separation.²²

The concern is that these liquid droplets can mature over time into more solid, gel-like, and eventually fibrillar assemblies. What starts as a reversible, functional concentration of proteins can harden into irreversible toxic aggregates. Mutations, oxidative stress, and aging can all accelerate this liquid-to-solid transition, making it a convergence point for multiple misfolding triggers.²³ The discovery has reshaped how researchers think about the earliest steps in aggregation, because it suggests the precursor is not always a single misfolded protein molecule but sometimes an entire compartment that has gone wrong.²⁴

When Amyloid Is Actually Useful

Not all amyloid-like structures are pathological. Organisms across all branches of life, from bacteria to humans, use regulated amyloid formation for beneficial purposes. In humans, the protein Pmel17 assembles into amyloid fibers inside specialized cellular compartments as part of the melanin biosynthesis pathway. Another example involves factor XII, a protein in the blood clotting cascade that is activated by contact with amyloid surfaces.²⁵ The key difference between functional and pathological amyloid is regulation. Functional amyloid formation is tightly controlled in time and space, confined to specific compartments where it cannot corrupt other proteins. Understanding how cells keep functional amyloid in check could eventually inform strategies for controlling its toxic counterpart.

Therapeutic Strategies Targeting Misfolded Proteins

The growing understanding of misfolding mechanisms has opened several therapeutic avenues. One of the most clinically advanced is the use of pharmacological chaperones, small molecules that bind directly to a disease-causing protein and stabilize its native fold. By propping up the correct structure, these molecules increase the fraction of protein that passes the cell’s quality-control checkpoints and reaches its intended destination.²⁶ In practice, these drugs mimic what a natural chaperone does but in a more targeted fashion, bridging the non-covalent contacts that a mutation has weakened.²⁷ This approach has already reached patients with cystic fibrosis and certain lysosomal storage disorders.

When the problem is not insufficient protein but too much of a toxic one, a different strategy applies. PROTACs are bifunctional molecules designed with two arms: one arm grabs the target protein, and the other recruits the cell’s own degradation machinery. The result is that the troublesome protein gets tagged with ubiquitin and fed to the proteasome for disposal.²⁸ Because one PROTAC molecule can catalyze the destruction of many copies of its target, the approach is potentially effective at very low doses.

Detecting Misfolded Proteins Earlier

Treating misfolding diseases is difficult in part because they are diagnosed late, often after substantial organ or brain damage has already occurred. Better detection tools could change that. Conjugated polyelectrolytes are a class of fluorescent molecules being developed for their ability to bind selectively to amyloid aggregates and produce distinct light signals upon doing so. By chemically modifying these molecules with specific targeting ligands, researchers have sharpened their selectivity enough to distinguish disease-specific biomarkers like amyloid-beta aggregates in real time, raising the possibility of noninvasive imaging for early-stage neurodegenerative disease.²⁹ These tools are still in the research stage, but the idea of catching aggregation before symptoms appear is one of the most promising frontiers in the field.